Cargando…
Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro
BACKGROUND: Laryngopharyngeal reflux (LPR) causes chronic cough, throat clearing, hoarseness, and dysphagia and can promote laryngeal carcinogenesis. More than 20% of the US population suffers from LPR and there is no effective medical therapy. Pepsin is a predominant source of damage during LPR whi...
Autores principales: | Samuels, Tina L., Blaine‐Sauer, Simon, Yan, Ke, Johnston, Nikki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446255/ https://www.ncbi.nlm.nih.gov/pubmed/37621274 http://dx.doi.org/10.1002/lio2.1102 |
Ejemplares similares
-
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
por: Blaine-Sauer, Simon, et al.
Publicado: (2023) -
Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics
por: Kurita, Takashi, et al.
Publicado: (2019) -
Multitime point pepsin testing can double the rate of the diagnosis of laryngopharyngeal reflux
por: Zhang, Jinhong, et al.
Publicado: (2021) -
Laryngeal complications of COVID‐19
por: Naunheim, Matthew R., et al.
Publicado: (2020) -
Retrograde fiberoptic endoscopy evaluation for patients with laryngeal edema
por: Alfaris, Abdullah Mohammed, et al.
Publicado: (2020)